CB
Cibus, Inc.
CBUS · NASDAQ
$1.54 -0.65% (-$0.01)
1M -8.33%
Market Cap $117.6M
P/E Ratio -
Div. Yield -
ROE 320.60%
Bulios Fair Price
$0.91
40.9% downside
Current Price
$1.54
Undervalued Fair Value Overvalued
According to Bulios Fair Price, CBUS is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
1 /100
Expensive P/B 7.94x
P/S 27.04x
EV/EBITDA N/A
Growth
100 /100
Growing Book val. growth 44.51%
Rev. growth 185.12%
FCF growth N/A
Profitability
0 /100
Weak Net margin 2,258.89%
Op. margin 1,240.90%
FCF margin 1,065.59%
Quality
0 /100
Poor ROE 320.60%
ROA 31.33%
Asset turnover 0.01x
Debt
24 /100
High Current ratio 1.62x
Int. coverage -3.33x
Debt/Equity 2.21x
Stability
7 /100
Unstable Rev. volatility 580.63%
EPS volatility 51,289.58%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CBUS
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Craig Wichner
Employees
118
Headquarters
San Diego
Upcoming events
12 NOV
Earnings
Upcoming earnings report